Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.530
-0.120 (-4.53%)
At close: Mar 3, 2026, 4:00 PM EST
2.530
0.00 (0.00%)
Pre-market: Mar 4, 2026, 5:45 AM EST
Allogene Therapeutics Revenue
In the year 2024, Allogene Therapeutics had annual revenue of $22.00K, down -76.84%.
Revenue (ttm)
$22.00K
Revenue Growth
-76.84%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
229
Market Cap
568.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% |
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% |
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% |
| Dec 31, 2021 | 114.09M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 282.08M |
| Lexicon Pharmaceuticals | 70.86M |
| MeiraGTx Holdings | 27.42M |
| Ocugen | 5.37M |
| YD Bio | 510.36K |
ALLO News
- 1 day ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 13 days ago - Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript - Seeking Alpha
- 26 days ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire
- 4 months ago - Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T - Seeking Alpha
- 4 months ago - Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire